PCI Pharma Services ("PCI" or the "Company"), a world-leading global contract development and manufacturing organization ...

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its ...

PCI Pharma Services has received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and ...

Mubadala’s investment is part of a strategic transaction co-led by Bain Capital and existing lead investor Kohlberg ...

The firms lead an investment valuing PCI Pharma at $10 billion, see the company benefiting from broader trends.

PCI Pharma Services, a Philadelphia-based biotherapy-focused contract development and manufacturing organization, has secured an investment co-led by Bain Capital and existing backer Kohlberg.

A Philadelphia-based pharmaceutical services company has just received a massive investment from two major private equity firms, reportedly catapulting its valuation to $10 billion.

Part of $1 Billion Investment Strategy, PCI Pharma Services Completes Acquisition of Ajinomoto Althea, Enhancing US Drug Product Manufacturing for Aseptic Filling of Prefilled Syringes & Cartridges.

A pharma business has announced a new three-year charity partnership with Hospice of the Valleys, which provides ...

PHILADELPHIA, PA — PCI Pharma Services has finalized the acquisition of Ajinomoto Althea, Inc. (Althea), a U.S.-based sterile fill-finish contract development and manufacturing organization ...

PCI Pharma Services plans to grow its largest manufacturing facility by more than 50%, pouring about $146 million into a 545,000-square-foot expansion of its Rockford facility.

Mubadala Investment Company, the Abu Dhabi-based sovereign wealth fund managing a global portfolio, is making a significant reinvestment in PCI Pharma Services (PCI).